Annexon, Inc.·4

Feb 20, 4:30 PM ET

Dananberg Jamie 4

4 · Annexon, Inc. · Filed Feb 20, 2026

Research Summary

AI-generated summary of this filing

Updated

Annexon (ANNX) CMO Jamie Dananberg Sells 5,290 Shares

What Happened
Jamie Dananberg, Chief Medical Officer of Annexon, sold 5,290 shares in an open-market transaction on February 18, 2026. The weighted average sale price was $5.10 per share for a total proceeds of $26,979. This was a sale (transaction code S) and, per the filing, the disposition was made to satisfy tax withholding obligations tied to RSU vesting.

Key Details

  • Transaction date: 2026-02-18; Form 4 filed on 2026-02-20 (reporting period: 2026-02-18).
  • Price details: multiple trades priced between $4.93 and $5.16; reported price is the weighted average $5.10. (F2: issuer/filing party can provide per-trade breakdown on request.)
  • Total shares sold: 5,290; total proceeds: $26,979.
  • Reason given: sale to cover tax withholding related to vested restricted stock units (RSUs) (F1). This is a routine tax-withholding sale (transaction code F in footnote context).
  • Shares owned after transaction: not specified in the provided filing excerpt.
  • Filing timeliness: Form 4 was filed two days after the transaction date; the filing does not indicate a late designation in the provided excerpt.

Context
Sales to cover taxes on vested RSUs are common and generally viewed as administrative rather than a signal of a change in insider sentiment. Purchases by insiders often carry more weight for investors seeking a bullish signal; routine withholding sales are typically neutral informationally.

Insider Transaction Report

Form 4
Period: 2026-02-18
Dananberg Jamie
CHIEF MEDICAL OFFICER
Transactions
  • Sale

    Common Stock

    [F1][F2]
    2026-02-18$5.10/sh5,290$26,97973,152 total
Footnotes (2)
  • [F1]The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs").
  • [F2]This transaction was executed in multiple trades in prices ranging from $4.93 to $5.16, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Signature
/s/ Jennifer Lew, Attorney-in-Fact|2026-02-20

Documents

1 file
  • 4
    form4-02202026_040203.xmlPrimary